June 18, 2025
Rewind Therapeutics Strengthens Scientific Advisory Board
Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan are...
Read More
January 25, 2023
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
– Claus Andersson, PhD, joins Rewind´s Board of Directors Leuven, Belgium, January...
Read More
November 29, 2022
Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team
– Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and...
Read More
October 19, 2022
ECTRIMS 2022, October 26-28, Amsterdam, The Netherlands
38th Congress of the European Committee for Treatment and Research in Multiple...
Read More
October 18, 2022
Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer
– Former Roche Head of Neuroimmunology strengthens Rewind´s neuroimmunology and neurodegeneration expertise...
Read More
September 22, 2021
Rewind Therapeutics appoints Anja Harmeier, PhD, MBA, as Chief Executive Officer
Leuven, Belgium, 22 September 2021 – Rewind Therapeutics (“Rewind”), a private Belgian...
Read More
September 2, 2020
Rewind Therapeutics appoints Kees Been as Non-Executive Director
Leuven, Belgium, 2 September 2020 – Rewind Therapeutics (“Rewind”), a private Belgian...
Read More